Evidence map›Paper›PMID 28660324›Full record

ReviewDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen2017

[R1 resection for gastric carcinoma].

K Ridwelski, J Fahlke, M Huß, R Otto, S Wolff

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

K RidwelskiAN-Institut für Qualitätssicherung in der operativen Medizin an der Otto-von-Guericke-Universität Magdeburg gGmbH, Leipziger Str. 44, 39120, Magdeburg, Deutschland. Karsten.Ridwelski@Klinikum-Magdeburg.de.
J FahlkeKlinik für Allgemein-, Viszeral- und Gefäßchirurgie, Johanniter-Krankenhaus Genthin-Stendal GmbH, Stendal, Deutschland.
M HußKlinik für Allgemein-, Viszeral- und Gefäßchirurgie, Johanniter-Krankenhaus Genthin-Stendal GmbH, Stendal, Deutschland.
R OttoAN-Institut für Qualitätssicherung in der operativen Medizin an der Otto-von-Guericke-Universität Magdeburg gGmbH, Leipziger Str. 44, 39120, Magdeburg, Deutschland.
S WolffAN-Institut für Qualitätssicherung in der operativen Medizin an der Otto-von-Guericke-Universität Magdeburg gGmbH, Leipziger Str. 44, 39120, Magdeburg, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The results reported in the literature in the context of an R1 situation for a resected gastric carcinoma are not uniform. An R1 situation worsens the prognosis for the long-term survival of patients. This is significant especially for low T stages and lymph node metastasis with 0-≤3 lymph node metastases. In higher tumor stages with extensive lymph node metastases, the survival difference between R0 and R1 resections is lower and frequently no longer significant. The frequency of R1 resection is approximately 5% (range 1.8-9%) and for adenocarcinoma of the esophagogastric junction (AEG tumors)> 10%. The data are mainly related to the oral and aboral resection line but there are only a few specifications on the circumferential margin. The risk of an infiltrated resection line increases with the size of the tumor (>5 cm), T3+4 and pN2/pN3 stages. Poorly differentiated signet ring cell or mucinous adenocarcinomas and carcinomas of the Bormann type 3+4 also lead to an increased R1 rate. In order to achieve an R0 resection, an intraoperative frozen section is the standard approach. Immediate reoperation should be performed in the case of tumor infiltration. If an R1 resection is detected only in the definitive histology, surgical re-excision to achieve an R0 resection is the standard approach in publications. Nevertheless, a reoperation is rare. Only 1 study showed 122 patients with 100% re-operations, which were successfully performed in 50 patients (41% R0). For the R0 group, median survival was extended from 18 months to 23 months. There are only sporadic literature data and no evidence for postoperative additive treatment (chemotherapy, radiotherapy and radiochemotherapy).

Indexed as

AdenocarcinomaCombined Modality TherapyEsophagogastric JunctionFemaleFrozen SectionsGastrectomyGuideline AdherenceHumansLymphatic MetastasisLymph Node ExcisionMaleMargins of ExcisionNeoadjuvant TherapyNeoplasm StagingPrognosisReoperationIntraoperative frozen sectionLong-term survivalPrognosisReoperationRisk factors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.